Paxlovid

Abstract

Coronavirus infection is a pandemic threat and the most dangerous disease of the 21st century. Despite the rigorous exertion of world-class researchers, there is no perfect cure for it. It has been seen in presently available studies that Paxlovid prevents the progression of diseases and reduces severity in patients tremendously who are at high risk of hospitalization and death. It is a safe oral antiviral drug and has the potential to treat infections from multiple corona variants including omicron which affects humans. Paxlovid is comparatively less expensive than other available effective medicines. Consequently, it reduces hospitalization and death and helps to plummet the economic burden on patients and the health-care system globally. This medicine is still under investigation, and numerous clinical trials are still underway. Its potential side effects are minor and well tolerated by research study participants. Studies show its benefits outweigh the risk, and it is an effective and good alternative for the treatment of coronavirus disease.

Computational Docking as a Tool in Guiding the Drug Design of Rutaecarpine Derivatives as Potential SARS-CoV-2 Inhibitors

“…Nevertheless, the emerging new SARS-CoV-2 VOCs displayed remarkable immune escape abilities and reduced the effectiveness of oral therapies [ 24 , 25 ]. For example, paxlovid was initially identified as being an efficacious anti-COVID-19 treatment, but it was unable to induce fundamental viral clearance and to attenuate the mortality among patients who contracted the omicron variant [ 26 , 27 ]. This indicates that more potent drugs are still required, specifically to tackle these VOCs.…”